

Name of the issue **Yatharth Hospital & Trauma Care Services Limited**

1. Type of issue (IPO/ FPO)	IPO
2. Issue size (Rs. crores) <i>Source: Prospectus dated July 30, 2023</i>	686.55
3. Grade of issue along with name of the rating agency	NA
4. Subscription level (number of times) <i>Source: Basis of Allotment advertisement dated August 5, 2023. This figure is including Anchor Portion and before technical rejections.</i>	26.42 times*
5. QIB holding (as a % of total outstanding capital) as disclosed to stock exchanges	
(i) allotment in the issue ⁽¹⁾	11.07.2023 13.13%
(ii) at the end of the 1 st Quarter immediately after the listing of the issue	30.09.2023 14.30%
(iii) at the end of 1 st FY ⁽²⁾	31.03.2024 NA
(iv) at the end of 2 nd FY ⁽²⁾	31.03.2025 NA
(v) at the end of 3 rd FY ⁽²⁾	31.03.2026 NA

⁽¹⁾ Source: Basis of Allotment Meeting Minutes dated July 11, 2023

⁽²⁾ Will be updated in due course

6. Consolidated Financials of the issuer

(Rs. in crores)

Parameters	FY23-24	FY24-25	FY25-26
Income from operations	NA	NA	NA
Net Profit for the period	NA	NA	NA
Paid-up equity share capital	NA	NA	NA
Reserves excluding revaluation reserves	NA	NA	NA

Note: Financials for the year ended March 31, 2024, 2025 and 2026 shall be updated in due course

7. Trading status in the scrip of the issuer
Company's Equity Shares are listed on both the BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE")

(i) at the end of 1 st FY (31 March 2024) ⁽¹⁾	NA
(ii) at the end of 2 nd FY (31 March 2025) ⁽¹⁾	NA
(iii) at the end of 3 rd FY (31 March 2026) ⁽¹⁾	NA

Note: ⁽¹⁾ Will be updated in due course

8. Change, if any, in directors of issuer from the disclosures in the offer document

<p>(i) During year ended (March 31, 2024)⁽¹⁾ Names of directors Appointed/ Resigned</p>	NA
<p>(ii) During year ended (March 31, 2025)⁽²⁾ Names of directors Appointed/ Resigned</p>	NA
<p>(iii) During year ended (March 31, 2026)⁽²⁾ Names of directors Appointed/ Resigned</p>	NA

Note: ⁽¹⁾ Change in Directors of Issuer are updated as on date

⁽²⁾ Change in Directors of Issuer is not updated as the relevant financial years have not been completed

9. Status of implementation of project/ commencement of commercial production

(i) as disclosed in the offer document	NA
(ii) Actual implementation	NA
(iii) Reasons for delay in implementation, if any	NA

10. Status of utilization of issue proceeds

(i) As Disclosed in the offer documents	569.71 cr
(ii) Actual Utilization	276.86 cr ⁽¹⁾
(iii) Reasons for deviation, if any	NA

(1) As on November 14, 2023

(Rs in Crores)

Particulars	Amount proposed to be funded from Net Proceeds	Estimated Utilisation of Net Proceeds in Fiscal 2024	Estimated Utilisation of Net Proceeds in Fiscal 2025
Repayment/ prepayment, in full or part, of certain borrowings availed of by our Company	100.00	100.00	-
Repayment/ prepayment, in full or part, of certain borrowings availed of by our Subsidiaries, namely, AKS and Ramraja	145.00	145.00	-
Funding capital expenditure expenses of our Company for two hospitals, namely, Noida Hospital and Greater Noida Hospital	25.64	25.64	-
Funding capital expenditure expenses of our Subsidiaries, AKS and Ramraja, for respective hospital operated by them	106.97	106.97	
Funding inorganic growth initiatives through acquisition and other strategic initiatives	65.00	Over a period of two Financial Years from the date of listing of the Equity Shares	
General corporate purposes	127.10	127.10	-
ii) Actual Utilisation			
Repayment/ prepayment, in full or part, of certain borrowings availed of by our Company	100.00	100.00	NA
Repayment/ prepayment, in full or part, of certain borrowings availed of by our Subsidiaries, namely, AKS and Ramraja	145.00	142.72	NA
Funding capital expenditure expenses of our Company for two hospitals, namely, Noida Hospital and Greater Noida Hospital	25.64	2.48	NA
Funding capital expenditure expenses of our Subsidiaries, AKS and Ramraja, for respective hospital operated by them	106.97	3.33	NA
Funding inorganic growth initiatives through acquisition and other strategic initiatives	65	0.00	
General corporate purposes	127.10	28.32	
(iii) Reasons for deviation, if any- NA			

11. Comments of monitoring agency, if applicable

- (a) Comments on use of funds
- (b) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document
- (c) Any other reservations expressed by the monitoring agency about the end use of funds

Nil

Nil

Nil

12. Price- related data

Designated Stock Exchange:

Issue price (Rs):

Listing Date:

BSE Limited
Rs.300/- per share
August 07, 2023

Price parameters	At close of listing day – August 07, 2023	At close of 30 th calendar day from listing day	At close of 90 th calendar day from listing day	As at the end of Mar 31, 2024 ⁽¹⁾		
				Closing price during the FY	High during the FY	Low during the FY
Market Price	333.75	366.90	361.75	NA	NA	NA
BSE Sensex	65,953.48	65,880.52	64,958.69	NA	NA	NA
Price parameters	As at the end of Mar 31, 2025 ⁽¹⁾			As at the end of March 31, 2026 ⁽¹⁾		
	Closing price during the FY	High during the FY	Low during the FY	Closing price during	High during the FY	Low during the FY
Market Price	NA	NA	NA	NA	NA	NA
BSE Sensex	NA	NA	NA	NA	NA	NA

Source: Stock Exchange data. Where the 30th day / 90th day/ March 31 of a particular year falls on a holiday, the immediately preceding trading day has been considered

(1) Will be updated in due course

13. Basis for Issue Price and Comparison with Peer Group & Industry Average

Accounting Ratio	Name of company	As disclosed in the offer document*	At the end of 1st FY (Mar 31, 2024)**	At the end of 2nd FY (Mar 31, 2025)**	At the end of 3rd FY (Mar 31, 2026)**
EPS (Basic)	Issuer: Standalone	10.09	NA	NA	NA
	Peer Group				
	Apollo Hospitals Enterprise Limited	56.97	NA	NA	NA
	Fortis Healthcare Limited	7.80	NA	NA	NA
	Narayana Hrudalaya Limited	29.85	NA	NA	NA
	Max Healthcare Institute Limited	11.38	NA	NA	NA
	Krishna Institute of Medical Sciences Limited	42.03	NA	NA	NA
	Healthcare Global Enterprises Limited	2.11	NA	NA	NA
	Global Health Limited	12.58	NA	NA	NA
	Industry Average	23.24	NA	NA	NA
EPS (Diluted)	Issuer: Standalone	10.09	NA	NA	NA
	Peer Group				
	Apollo Hospitals Enterprise Limited	56.97	NA	NA	NA
	Fortis Healthcare Limited	7.80	NA	NA	NA
	Narayana Hrudalaya Limited	29.85	NA	NA	NA
	Max Healthcare Institute Limited	11.36	NA	NA	NA
	Krishna Institute of Medical Sciences Limited	42.03	NA	NA	NA
	Healthcare Global Enterprises Limited	2.10	NA	NA	NA
	Global Health Limited	12.57	NA	NA	NA
	Industry Average	23.24	NA	NA	NA
(P/E)	Issuer: Standalone	29.73	NA	NA	NA
	Peer Group				
	Apollo Hospitals Enterprise Limited	89.44	NA	NA	NA
	Fortis Healthcare Limited	40.36	NA	NA	NA
	Narayana Hrudalaya Limited	33.29	NA	NA	NA
	Max Healthcare Institute Limited	52.66	NA	NA	NA
	Krishna Institute of Medical Sciences Limited	42.44	NA	NA	NA
	Healthcare Global Enterprises Limited	151.02	NA	NA	NA
	Global Health Limited	52.44	NA	NA	NA
	Industry Average	65.95	NA	NA	NA

RoNW%	Issuer: Standalone	35.95	NA	NA	NA
	Peer Group				
	Apollo Hospitals Enterprise Limited	13.22	NA	NA	NA
	Fortis Healthcare Limited	8.13	NA	NA	NA
	Narayana Hrudalaya Limited	28.44	NA	NA	NA
	Max Healthcare Institute Limited	14.89	NA	NA	NA
	Krishna Institute of Medical Sciences Limited	20.14	NA	NA	NA
	Healthcare Global Enterprises Limited	3.41	NA	NA	NA
	Global Health Limited	13.43	NA	NA	NA
	Industry Average	14.52	NA	NA	NA
NAV per share	Issuer: Standalone	27.93	NA	NA	NA
	Peer Group				
	Apollo Hospitals Enterprise Limited	431.02	NA	NA	NA
	Fortis Healthcare Limited	95.93	NA	NA	NA
	Narayana Hrudalaya Limited	104.30	NA	NA	NA
	Max Healthcare Institute Limited	76.32	NA	NA	NA
	Krishna Institute of Medical Sciences Limited	208.62	NA	NA	NA
	Healthcare Global Enterprises Limited	61.86	NA	NA	NA
	Global Health Limited	90.54	NA	NA	NA
	Industry Average	152.66	NA	NA	NA

* Sourced from Prospectus | All the financial information for listed industry peers mentioned above is on a consolidated basis and is sourced from the financial results of the respective company for the year ended March 31, 2023 submitted to stock exchanges.

** will be updated in due course

- (1) P/E Ratio: P/E Ratio has been computed based on the closing market price of equity shares on BSE on June 30, 2023 divided by the Basic EPS provided under Note 2 below.
- (2) EPS: Basic & Diluted EPS refers to the EPS sourced from the financial results of the respective company for the year ended March 31, 2023.
- (3) Net Asset Value: Net Asset Value is computed as the Equity attributable to owners of the company at the end of year March 31, 2023 divided by the equity shares outstanding as on March 31, 2023.
- (4) Return on Net Worth % (RONW %) is calculated as Profit after taxes attributable to owners of the company as a percentage of Equity attributable to owners of the company at the end of year March 31, 2023.)

14. Any other material information

Particulars	Date
Company informed stock exchanges that Search Operation was carried out by Income Tax Department at various locations of the Company from 19th October, 2023 to 22nd October, 2023.	22-Oct-23

Source: Stock Exchange filings; For further updates and information, please refer stock exchange websites i.e. www.bseindia.com and www.nseindia.com